SCHEMBL7044973

SCHEMBL7044973

CN(C)C(=O)c1cccc(CS)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.62
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.45
ERN1 O75460 2/20 0.43
HSD17B1 P14061 2/20 0.43
HSD17B2 P37059 2/20 0.43
KIF11 P52732 1/20 0.43
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FAAH O00519 1/20 0.41
MGLL Q99685 1/20 0.41
HPGD P15428 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LOX P28300 1/20 0.41
BRD4 O60885 1/20 0.41
ANPEP P15144 1/20 0.41
ENPEP Q07075 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27484385 0.86 KMT2A (0.49) FOLH1KMT2AMEN1L3MBTL1ERN1
SCHEMBL3996930 0.84 KMT2A (0.53) FOLH1KMT2AMEN1L3MBTL1ERN1
SCHEMBL29866123 0.84 KMT2A (0.53) FOLH1KMT2AMEN1L3MBTL1ERN1
SCHEMBL322040 0.84 KMT2A (0.53) KMT2AMEN1L3MBTL1ERN1HSD17B1
SCHEMBL3276164 0.82 KMT2A (0.51) FOLH1KMT2AMEN1L3MBTL1ERN1
SCHEMBL5567925 0.82 KMT2A (0.56) KMT2AMEN1L3MBTL1ERN1HSD17B1
SCHEMBL30240849 0.82 KMT2A (0.56) KMT2AMEN1L3MBTL1ERN1HSD17B1
SCHEMBL929805 0.82 LOXL2 (0.60) KMT2AMEN1L3MBTL1ERN1HSD17B1
SCHEMBL29866166 0.82 KMT2A (0.51) FOLH1KMT2AMEN1L3MBTL1ERN1
SCHEMBL2537972 0.82 KMT2A (0.51) FOLH1KMT2AMEN1L3MBTL1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9809590-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-11-07 US disclosed
EP-0950649-B1 A process for preparing oxyalkylene derivatives in the presence of phosphine oxides MITSUI CHEMICALS INC (JP) 2003-03-26 EP disclosed
US-6130346-A ESTERIFICATION, CARBONATION, SULFONATION, ETHERIFICATION MITSUI CHEMICALS, INC. (JP) 2000-10-10 US disclosed
EP-0950649-A1 A process for preparing oxyalkylene derivatives in the presence of phosphine oxides Mitsui Chemicals, Inc. (JP) 1999-10-20 EP disclosed